single20MG
Semaglutide
20MG Protocol
Semaglutide 20MG
Injection Freq.
Inject once weekly
Cycle Sched.
Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation
Reconstitution
3.0 mL BAC water
Significant weight loss (~10–15% mean in trials with lifestyle support)
Improved glycemic control via glucose-dependent insulin secretion
Reduced appetite and food intake via CNS GLP-1 signaling
Cardiovascular outcome benefits reported (reduced MACE risk)
Once-weekly dosing convenience
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 250 mcg (0.25 mg) | 4 |
| 2 | Weeks 5–8 | 500 mcg (0.5 mg) | 7.5 |
| 3 | Weeks 9–12 | 1000 mcg (1.0 mg) | 15 |
| 4 | Weeks 13–16 | 1700 mcg (1.7 mg) | 25.5 |
| 5 | Weeks 1+ | 2400 mcg (2.4 mg) | 36 |
Inject once weekly
Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation
Semaglutide (semaglutide) is described as a GLP-1 receptor agonist with high similarity to native human GLP-1. In the protocol, weight and metabolic effects are explained through three coordinated mechanisms: central appetite suppression (reduced hunger and food intake), delayed gastric emptying (slower nutrient delivery), and improved glycemic control via glucose-dependent insulin secretion with reduced glucagon signaling. The page highlights why dosing can be weekly: semaglutide is engineered to bind albumin and resist DPP-4 degradation, producing an extended half-life of about 7 days. Clinical trials summarized in the protocol report mean body-weight reductions in the ~10–15% range when paired with lifestyle intervention, and the page notes the FDA-approved maintenance approach for chronic weight management. Overall, Semaglutide is positioned as an incretin therapy that primarily reduces intake and improves glucose handling, with gradual titration used to manage gastrointestinal side effects.
Nausea, vomiting, diarrhea, constipation, abdominal pain (dose-dependent GI effects)
Injection-site reactions (redness/swelling/irritation)
Hypoglycemia risk when combined with insulin/sulfonylureas
Rare: pancreatitis, gallbladder disease, acute kidney injury
Thyroid C-cell tumors seen in rodents (human relevance uncertain)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)